You just read:

Janssen's Stelara and Pfizer's Xeljanz Battle Takeda's Entyvio to Claim the Preferred Alternate Mechanism of Action Position in Inflammatory Bowel Disease Patients Who Are Being Switched from Their Current Treatment

News provided by

Spherix Global Insights

Jan 14, 2019, 15:48 ET